DENVER, Feb. 24, 2011 /PRNewswire/ -- (OTC Bulletin Board: OMBP): Omni Bio Pharmaceutical, Inc. ("Omni Bio") today announced that effective March 1, 2011, Dr. James Crapo will become its Chief Executive Officer. The board of directors of the Company anticipates appointing Dr. Crapo as a director in the near term. Dr. Charles Dinarello, who has served as Omni Bio's acting Chief Executive Officer since its inception in March 2009, will become Omni's Chief Scientific Officer and Chief Medical Director. Dr. Dinarello will oversee Omni Bio's plan to expand its activities in filing for new IND's ("Investigational New Drug Application") for human clinical trials in additional immunological and infectious disease classifications. Dr. Crapo commented, "The science being developed by Omni Bio regarding new clinical indications for Alpha-1 antitrypsin ("AAT") is extremely exciting and I believe that it promises to be a major advance in the prevention and control of multiple human diseases. It will be a privilege to help move this field of work as rapidly as possible into approved clinical applications."
Dr. Crapo has served on Omni Bio's Scientific Advisory Board since March 2009. He is currently a Professor at National Jewish Medical and Research Center and served as its Executive Vice President of Academic Affairs and Chairman of Medicine from June 1996 to 2004. His prior business experience includes serving as CEO of Aeolus Pharmaceuticals, Inc. in 2004. Aeolus is focused on developing a new class of metalloporphyrins for use as catalytic antioxidants. He currently serves on the Board of Lifevantage Corporation, a maker of science-based solutions to oxidative stress. He was the first scientist to extend Dr. Irwin Fridovich's and Dr. Joe McCord's original discovery of superoxide dismutase, a natural
|SOURCE Omni Bio Pharmaceutical, Inc.|
Copyright©2010 PR Newswire.
All rights reserved